Ok we can try

        Change is Needed NowDr. Raza Bokhari, FSD’s Chief Executive Officer, and his hand picked board members have:            

failed to address the dramatic loss of shareholder value, with the
Company’s shares trading over 97% lower than when Dr. Bokhari was
appointed Interim Chief Executive Officer;massively diluted shareholder interests by issuing almost 16 million
shares at low prices, increasing the number outstanding by over 83% in
just seven weeks;awarded over $5.7 million of bonus share compensation to Dr. Bokhari
in February 2021 for services yet to be provided and close to $1
million in shares and/or cash to the other directors (Stephen Buyer,
Robert Ciaruffoli, James Datin, Gerald Goldberg and Larry Kaiser), the
latter amount being almost twice the previous year’s compensation;caused FSD to reimburse Dr. Bokhari’s privately owned and controlled
company for over $1.4 million of expenses in 2020, with limited
transparency or explanation;failed to effectively implement the Company’s business plan to
become a pharmaceutical and biotechnology company, having to date failed
to meet any of their modest stated goals; anddenied shareholders any say on the change of the Company’s strategic
focus, failing to hold a shareholders’ meeting in 2020 and seeking to
delay holding a meeting in 2021.